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Edited by Gianni CesareniAbstract The high cGMP sensitivity of cAMP-dependent
protein kinase A (type II) (PKAII) from invertebrates led to
the hypothesis that cGMP directly activates PKAII under
physiological conditions. We tested this idea using PKAII
holoenzyme puriﬁed from the honeybee brain in an assay with
short stimulation times. In the presence of very low cAMP
concentrations, we found a synergistic increase in PKAII
activation by physiological cGMP concentrations. Cloning
honeybee regulatory subunit RII and phylogenetic comparison
of the two cyclic nucleotide-binding sites of RII reveal a high
relation of domain A of insect RII with cGMP-binding domains
of cGMP-dependent protein kinases.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The cAMP signal transduction system plays a central role in
many cellular processes ranging from proliferation, diﬀerenti-
ation and growth to synaptic plasticity in the nervous system
[1]. Cyclic AMP-dependent protein kinases (PKA), the major
mediators of cAMP actions, are tetrameric enzymes (R2C2)
that consist of two regulatory subunits (R) and two catalytic
subunits (C). In mammals, four genes encode two classes of R
subunits (RIa; b and RIIa; b) and three genes encode the cat-
alytic subunits (Ca; b; cÞ [2]. Analysis of catalytic and regula-
tory subunits (R) from numerous species, including
invertebrates and protozoans, demonstrates the high conser-
vation of PKA subunits throughout the animal kingdom [1,3].
Dissociation of the C subunits and thus activation of PKA is
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domains, respectively [4,5]. Within each domain, the phos-
phate-binding cassette (PBC), a short sequence of about 20
amino acids, interacts with the cyclic nucleotide [6,7]. The
PBCs of the R subunits are highly conserved and diﬀer in only
a few amino acids from the PBC of the cGMP-dependent
protein kinases (PKG) [2]. Although a few amino acids in the
PBCs are very critical for nucleotide speciﬁcity, it is the PBC in
total that determines the individual nucleotide speciﬁcity of a
given R subunit [8–11]. While activation of mammalian PKA
requires a 50- to 100-fold higher concentration of cGMP
compared to cAMP [10], the discrimination between cAMP
and cGMP is not so clear in invertebrates. In some cases, PKA
activation requires much lower cGMP concentrations [12–14]
and in Trypanosoma brucei, PKA is activated only by cGMP
[15]. In this study, we test the hypothesis whether cAMP and
cGMP are both involved in direct PKA activation as proposed
in recent in vivo studies in honeybees [16–18].2. Materials and methods
2.1. Materials
Apis mellifera were taken from a regular hive. [c-32P]ATP (5000 Ci/
mmol) was purchased from NEN Life Science Products (Brussels,
Belgium). Phosphatase inhibitor I1 was puriﬁed from bovine brain
according to the procedure described for skeletal muscle [19]. PKA
inhibitor peptide, PKI (6–22) and all other chemicals were obtained
from Sigma (Deisenhofen, Germany).
2.2. Puriﬁcation of the PKAII holoenzyme
PKAII holoenzyme was puriﬁed according to the methods of [12,20].
Brains of 100 bees (120 mg) were dissected and homogenized in 5 ml
buﬀer-A (50 mM Tris–HCl, pH 7.8, 1 mM EDTA, 1 mM EGTA and
10 mM 2-mercaptoethanol). After centrifugation (50 000  g; 30 min),
the supernatant was applied to a DEAE-Sepharose column (2 ml,
equilibrated in buﬀer-A). Fractions between 0.18 and 0.23 M NaCl,
containing PKAII activity, were dialyzed against buﬀer-B (10 mM
sodium phosphate-buﬀer, pH 6.8, 1 mM EDTA, 1 mM EGTA and 10
mM 2-mercaptoethanol) and passed over a CM-Sephadex column (5
ml) equilibrated in buﬀer-B. The ﬂow-through fraction, containing
PKAII holoenzyme, was slowly (2 ml/h) passed over an adenosine
30:50-cyclic monophosphate agarose (C-8) aﬃnity column (0.5 ml).
After washing with 15 ml of 2 M NaCl in buﬀer-B, followed by 15 ml
buﬀer-B, the RII subunit was eluted by 8 M urea in buﬀer-B. The
fractions (0.2 ml) containing RII were dialyzed in buﬀer-B containing
0.1 M NaCl. The ﬂow-through fraction of the aﬃnity column, con-
taining the catalytic subunit, was dialyzed against buﬀer-B and passed
over a CM-Sephadex column (0.5 ml). After washing with buﬀer-B, the
C subunit was eluted with 0.5 M NaCl. The fractions (0.2 ml) con-
taining catalytic activity were dialyzed against buﬀer-A containing 0.1
M NaCl. Fractions with puriﬁed RII and C subunits were pooled and
the reconstituted PKAII holoenzyme was separated from free subunitsation of European Biochemical Societies.
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M NaCl) and used immediately.
2.3. Determining PKA activity
PKA activation by a short (30 s) cyclic nucleotide stimulation was
measured by using phosphatase inhibitor 1 (I1), a speciﬁc PKA sub-
strate [21]. For phosphorylation, samples of the puriﬁed PKAII ho-
loenzyme (10 ll) were mixed with 10 ll phosphorylation buﬀer (50 mM
Tris-buﬀer, pH 7.5, 0.1 M NaCl, 30 lM ATP, 1 lCi [c-32P]ATP (5000
Ci/mmol), 20 mM MgCl2, 10 mM 2-mercaptoethanol and 1 lg I1
boiled for 2 min prior to use). The phosphorylation mixture contains
cAMP and/or cGMP at concentrations as indicated in Section 3. After
incubation for 30 s at 20 C, the reactions were terminated by adding 5
ll of SDS-sample buﬀer (0.5 M Tris-buﬀer, pH 6.8, containing 5%
sodium dodecyl sulfate (SDS), 5% mercaptoethanol, 20% glycerol, and
0.1% bromophenol blue). SDS–PAGE and determination of 32P-in-
corporation into I1 were quantiﬁed as described in [18].
2.4. Cloning of the regulatory subunit RII of honeybee PKA
The AmPKA-R2 mRNA sequence (Accession No. AJ698737) was
identiﬁed by using the tBLASTn and BLASTn algorithms (default
parameters) to search a honeybee EST library [22] and the honeybee
genome (www.hgsc.bcm.tmc.edu/projects/honeybee/). Speciﬁc primers,
hybridizing in the 50 and 30 untranslated regions, were synthesized from
these sequences.
Five honeybee workers (Apis mellifera carnica) were collected from
the hive and immobilized on ice. After dissection, brains were imme-
diately crushed, using a cell homogenizer, in a 1.5 ml tube containing
Trizol reagent and total RNA was extracted according to the manu-
facturer’s instructions (Invitrogen, Karlsruhe, Germany). Two micro-
grams of RNA was reverse-transcribed by using an oligo-d(T)18 primer
and the Revertaid H minus ﬁrst-strand cDNA synthesis kit (MBI
Fermentas, St.Leon-Rot, Germany). This cDNA was used as template
in a PCR, including 1 unit of Gentherm polymerase (Rapidozym,
Berlin, Germany), dNTPs (250 lM each dNTPs), the direct primer 50-
ATTTGCCTATTATTTGCCAGTTA-30 (1 lM), the reverse primer
50-AAAACACGCGGATGAGATTC-30 (1 lM) and the PCR buﬀer
(16 mM (NH4)2SO4, 67 mM Tris–HCl (pH 8.8), 1.5 mM MgCl2 and
0.01% Tween 20). The PCR protocol consisted of 25 cycles of 30 s at 95
C, 30 s at 62 C, and 1 min at 72 C, followed by a 10 min incubation
at 72 C. The ampliﬁed cDNA was ligated into the pCR4-TOPO
cloning vector and TOP10 Escherichia coli cells were transformed with
the ligation product (Invitrogen, Karlsruhe, Germany). Several clones
obtained from diﬀerent RT-PCR, were sequenced and the identiﬁed
sequence was deposited at GenBank/EMBL.
2.5. Computational analysis
The phylogenetic trees were realized from sequence alignment of
AmPKA-R2, human PKA-R1a (NM-002734) and b (NM-002735),
PKA-R2a (NM-004157) and b (NM-002736),Mus musculus PKA-R2a
(NM-008924) and b (NM-011158), Drosophila melanogaster PKA-R2
(NM-176117) and PKA-R1 (P16905), Caenorhabditis elegans PKA-R
(NM-076598), Aplysia californica PKA-R1 (CAA44246) and PKA-R2
(AY387673), Anopheles gambiae PKA-R2 (XM-315029), Apis mellifera
PKG (AF469010), Drosophila melanogaster PKG (AAA28459), Bom-
byx mori PKG (AF465600), human PKG1 (NM006258) and PKG2
(NM006259), Mus musculus PKG1 (NM011160) and PKG2 (NM-
008926) by the ClustalW alignment method with the Gonnet series
protein weight matrix (default parameters) for the whole sequence
alignment in Fig. 2 and by the Jotun Hein method with the structural
protein weight matrix (Default parameters) for the PBC alignments in
Fig. 3 (Megalign software – DNASTAR, Madison, WI, USA).3. Results and discussion
3.1. Synergistic activation of puriﬁed PKAII holoenzyme by
cAMP and cGMP
Previous in vivo studies on the interaction between the NO/
cGMP-pathway and PKA activation in honeybees led to the
conclusion that PKAII activity is directly modulated by both
cAMP and cGMP [16–18]. To test this hypothesis, we used
PKAII holoenzyme puriﬁed from bee brain and puriﬁedphosphatase inhibitor-1 (I-1) as substrate to exclude enzyme
activities other than PKA [16–18,21]. The separate puriﬁcation
of the C subunits and the RII subunits followed by a recon-
stitution of the RII2C2 holoenzyme allows the veriﬁcation of
their purity at various steps. By crosslinking potentially bound
proteins with the subunits or the holoenzyme, followed by
SDS–PAGE separation and sensitive silver staining techniques
or Western blot analysis with antibodies against the subunits,
we excluded the possibility that other proteins are bound to
one of the subunits or the reconstituted holoenzyme. However,
due to the resolution of the separation techniques (ionic
strength and molecular weight), a contamination with small
peptides cannot be totally excluded.
In order to keep close to physiological activation dynamics,
we used a short cyclic nucleotide stimulation of 30 s. Under
these conditions, half-maximal activation of PKAII requires
0.1 lM cAMP or 3 lM cGMP (Fig. 1A). Both the cAMP and
the cGMP activation are totally abolished by a speciﬁc PKA
inhibitor peptide (Fig. 1B), demonstrating that the measured
activity is due to the action of the catalytic subunit.
However, with respect to the physiological situation in living
cells, the isolated stimulation by either cAMP or cGMP used in
most biochemical studies is not well suited to uncover potential
eﬀects of the coincident presence of cAMP and cGMP on PKA
activation (or any other targets of the cyclic nucleotides). The
latter is a well-known problem of physiological studies on intact
cells or intact animals, where a clear-cut discrimination between
cGMP and/or cAMP action on their targets is often not possible
[23]. Especially, the cGMP production via the soluble guanylyl
cyclase (sGC), which is not coupled to a distinct receptor and is
directly activated by the diﬀusible nitric oxide (NO), led to the
hypothesis that cGMP, at low cAMP concentrations, may
directly activate PKAII [16–18].
Based on this hypothesis, we tested the eﬀect of cGMP on
PKAII holoenzyme activation in the presence of low con-
centrations of cAMP (Fig. 1C). CyclicGMP at low physio-
logical concentrations is unable to activate PKAII. However,
in the presence of cAMP in the nanomolar range (25 or 33
nM) that alone activates PKAII in the range of 4–10%, these
low cGMP concentrations lead to a synergistic and signiﬁcant
additional PKAII activation. Whereas, for example, 250 nM
cGMP alone activates PKAII less than 1%, it leads to an
additional 12% PKAII activation in presence of 25 nM
cAMP, which alone activates PKAII about 4%. Although
only in the range 10–15% of maximal PKAII activation, the
observed synergistic eﬀect is suﬃcient to explain the in vivo
PKAII activation during associative and non-associative
learning in the honeybee, which has been proposed to be
mediated by direct cGMP action on PKAII [16–18]. More-
over, the synergistic eﬀect of cGMP on PKAII activity at low
cAMP concentrations points to a diﬀerence in the properties
of the two cAMP-binding domains of the regulatory subunit.
Our ﬁndings are consistent with the idea that the cAMP-
binding domain B (slow-binding domain), which is occupied
ﬁrst, is sensitive to cAMP but not to cGMP. Thus, the initial
binding of cAMP to domain B is required to expose binding
domain A (fast binding domain), which seems to be more
sensitive to cGMP as compared to domain B. This, together
with the frequently reported diﬀerence in cAMP versus cGMP
selectivity of invertebrate PKAII and mammalian PKAII,
prompted us to analyze the regulatory subunit and especially
the cAMP-binding domains in more detail.
Fig. 1. Cyclic nucleotide-dependent activation of cAMP-dependent
protein kinase A (PKAII) from honeybees. Activity of PKAII-holo-
enzyme puriﬁed from honeybee brains was determined using phos-
phatase inhibitor I as substrate. Kinase activation by cAMP and/or
cGMP was terminated after 30 s to keep stimulation within a physi-
ological time range. The 32P-incorporation into the substrate was
normalized with respect to the maximal value (20 lM cAMP). (A)
Activation of PKAII holoenzyme by either cAMP or cGMP at con-
centrations as indicated. The arrows indicate concentrations required
for half-maximal activation. Each value presents the mean (S.E.M.)
of at least 8 measurements. (B) Addition of the speciﬁc PKA inhibitor
peptide PKI-(6-22) amide completely abolishes the cAMP (10 lM) or
cGMP (10 lM) stimulated kinase activation. Each column presents the
mean (S.E.M.) of 10 measurements. (C) Eﬀect of cGMP on PKAII
activity in the absence and presence of cAMP. Activation of PKAII by
cGMP (0.1–3.3 lM) in the presence of cAMP signiﬁcantly diﬀers from
activation by cGMP alone. Each point presents the mean (S.E.M.) of
at least 12 measurements (t test: P < 0:001).
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PKAII regulatory subunit
As expected, the amino acid sequence of AmPKA-R2 re-
veals all general structural features of the PKA-R2 gene fam-
ily, including dimerization site, catalytic subunit binding site
with the autophosphorylation site, and the two cAMP-binding
domains comprising the PBC [1,20].
Phylogenetic analysis of several PKA-Rs and PKGs show
that the compared proteins are clustered in separate groupsthat are consistent with accepted phylogenetic relationships
(Fig. 2). AmPKA-R2 shows the highest similarity with PKA-
R2 from Anopheles gambiae (71.1% amino acids identity) and
Drosophila melanogaster (61.1% amino acids identity).
Since the biochemical data suggest a diﬀerence between the
cAMP-binding domains, the PBC domains A and B from
AmPKA-R2 were compared with the corresponding sequences
of PKA regulatory subunits and PKGs of diﬀerent species. A
phylogenetic tree of the PBC domains A and B was realized
with the Jotun Hein method by using the structural protein
weight matrix of the DNASTAR software. This alignment
method was preferred because it gives higher scores to residues
that are chemically and spatially similar. Analysis using the
ClustalW slow-accurate method with the Gonnet protein
weight matrix revealed similar results as compared to the Jotun
Hein analysis (data not shown).
The analysis of the diﬀerent PBC domain A shows that the
ﬁrst branching of the tree separates PKGs and PKA-Rs
(Fig. 3A). In the PKA-R branching, there is an important
divergence between the diﬀerent PBCs. Indeed, the Drosophila
PBC is diverging early in the PKA-R branching, followed by
the Anopheles and the honeybee PBCs (Fig. 3A). The next
branching separates the Aplysia sequence from a group com-
prising the mammalian PKA-R2 and all analyzed PKA-R1
domains that are the most distant from the root of the tree.
In the PBCs domain B tree, the ﬁrst branching is also sep-
arating PKGs and PKA-Rs (Fig. 3B). In the PKA-R branch-
ing, the diﬀerent domains are clustered in sub-groups that are
more distant from the root of the tree and more nucleotide
substitutions are used to construct this tree in comparison with
the domain A tree. In the PKA-R group, the ﬁrst branching
separates PKA-R1 from PKA-R2 subunits. Interestingly, the
diﬀerent sub-groups composing the PKA-R group are not
totally consistent with accepted phylogenetic relationships.
For example, the Drosophila PKA-R2 sequence is localized in
the mammalian PKA-R2 sub-group rather than in the insects
sub-group. It is unlikely that the Drosophila PBC domain B is
more related to mammalian PBC domain B. Indeed, the
Drosophila PBC is presenting 90.5% identity to the Anopheles
PBC, 81% to the honeybee and the human PKA-R2b PBCs,
and 85.7% identity to the human PKA-R2a domain. This
classiﬁcation is probably due to the fact that the PBC domain
B of PKA-Rs is highly conserved and composed of short
stretch of sequence.
These phylogenetic tree analyses indicate that the PBC do-
main A of insect PKA-R2s are more related to a common
ancestor of PKA-R2 and PKGs PBCs than the PBC domain A
of other PKA-R subunits. On the contrast, the domain B
analysis shows that all the PKA-R domains are clustered in
sub-groups much more distant from the root of the tree, sug-
gesting that they are less related to PKGs PBCs.
Finally, the diﬀerent sequences were manually annotated by
focusing on conserved amino acids within the diﬀerent PBCs,
because these are likely to represent residues that serve im-
portant functions (Fig. 3C and D). This annotation shows that
the sequences of PKG and PKA-R2 PBCs A and B are highly
conserved and that almost all amino acids interacting with the
cyclic nucleotide are identical, except at position 15, which is
characterized by an alanine in PKA-Rs and by a threonine or a
serine in PKGs (Fig. 3C and D). Other amino acids composing
the PBCs domains A and B are particular to all PKA-Rs
(Fig. 3C and D – light gray boxes) or to all PKGs (Fig. 3C and
Fig. 2. Phylogenetic analysis of PKA-R subunits and PKGs. The predicted amino acid sequence of AmPKA-R2 was compared with diﬀerent
proteins. The distances between the branches correspond to sequence divergence. The scale indicates the nucleotide substitution.
Fig. 3. Analysis of the PBCs of PKA-R subunits and PKG. The phylogenetic tree of PBCs domains A (A) and B (B) compared the predicted amino
acid sequence of AmPKA-R2 with diﬀerent proteins. The distance between the branches corresponds to sequence divergence. The scale indicates the
nucleotide substitution. The amino acids sequences of PBC domains A (C) and B (D) have been manually notated. The boxes indicate amino acids,
which are identical in all the sequences; the asterisks mark the amino acids directly interacting with the cyclic nucleotide. The light and dark gray
boxes show the amino acids that are identical in all PKA-R or all PKGs, respectively. The black boxes show PKGs conserved amino acids that are
also present in PKA-R subunits. The position of the ﬁrst amino acid of PBC domains is indicated on the left and the relative position of each amino
acid in the PBC is indicated at the top of the alignment.
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amino acids are also important in determining the PBC spec-
iﬁcity either for cAMP or for cGMP. Interestingly, the analysisof the domain A showed that a conserved leucine in position 9
of all PKGs is also found in the PBC domain A of insects
PKA-R2 and that the conserved asparagine in position 15 of
220 G. Leboulle, U. M€uller / FEBS Letters 576 (2004) 216–220all PKGs is also found in all PKA-R2 domain A (Fig. 3C –
black boxes). Such similarities between PKGs and PKA-Rs are
not found in the PBC domain B (Fig. 3D).
In conclusion, these results indicate that the PBC domain A
of insects PKA-R2 is an atypical cyclic nucleotide-binding
domain. The phylogenetic and the sequence analyses demon-
strate that it is a cAMP-binding site, but it also shows simi-
larities to the PBC domain A of PKGs that could explain the
synergistic action of cAMP and cGMP on PKA activation in
the honeybee. However, only site directed mutagenesis exper-
iments could validate these predictions.
Although we have only demonstrated a synergistic activa-
tion of PKAII by cAMP and cGMP in honeybees, the
sequence comparison points to a general feature of insect
PKAIIs with their corresponding consequences regarding the
interaction between the cGMP- and the cAMP-regulated sig-
naling cascades.
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